VEGFR-1 blockade disrupts peri-implantation decidual angiogenesis and macrophage recruitment by unknown
VASCULAR CELL
Douglas et al. Vascular Cell 2014, 6:16
http://www.vascularcell.com/content/6/1/16RESEARCH Open AccessVEGFR-1 blockade disrupts peri-implantation
decidual angiogenesis and macrophage
recruitment
Nataki C Douglas1*, Ralf C Zimmermann1, Qian Kun Tan2, Chantae S Sullivan-Pyke2, Mark V Sauer1,
Jan K Kitajewski2 and Carrie J Shawber2Abstract
Background: Angiogenesis and macrophage recruitment to the uterus are key features of uterine decidualization;
the progesterone-mediated uterine changes that allow for embryo implantation and initiation of pregnancy. In the
current study, we characterized the expression of vascular endothelial growth factor receptor-1 (VEGFR-1) in
macrophages and endothelial cells of the peri-implantation uterus and determined if VEGFR-1 function is required for
decidual angiogenesis, macrophage recruitment, and/or the establishment of pregnancy.
Methods: Expression of VEGFR-1 in uterine endothelial cells and macrophages was determined with
immunohistochemistry. To assess the effect of continuous VEGFR-1 blockade, adult female mice were given VEGFR-1
blocking antibody, MF-1, every 3 days for 18 days. After 6 doses, females were mated and a final dose of MF-1 was
given on embryonic day 3.5. Endothelial cells and macrophages were quantified on embryonic day 7.5. Pregnancy
was analyzed on embryonic days 7.5 and 10.5.
Results: F4/80+ macrophages are observed throughout the stroma and are abundant adjacent to the endometrial
lumen and glands prior to embryo implantation and scatter throughout the decidua post implantation. VEGFR-1
expression is restricted to the uterine endothelial cells. F4/80+ macrophages were often found adjacent to
VEGFR-1+ endothelial cells in the primary decidual zone. Continuous VEGFR-1 blockade correlates with a significant
reduction in decidual vascular and macrophage density, but does not affect embryo implantation or maintenance of
pregnancy up to embryonic day 10.5.
Conclusions: We found that VEGFR-1 functions in both decidual angiogenesis and macrophage recruitment to the
implantation site during pregnancy. VEGFR-1 is expressed by endothelial cells, however blocking VEGFR-1 function in
endothelial cells results in reduced macrophage recruitment to the uterus. VEGFR-1 blockade did not compromise
the establishment and/or maintenance of pregnancy.
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Implantation of the fertilized oocyte induces uterine
decidualization, the rapid proliferation and differenti-
ation of stromal fibroblasts into glycogen and lipid rich
decidual cells. Endothelial cells within the decidua prolif-
erate to form a rudimentary vascular plexus necessary to* Correspondence: nd2058@cumc.columbia.edu
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Cells of the innate immune system, including natural
killer cells and macrophages, infiltrate the decidua and
function to establish and maintain maternal–fetal tolerance
[4,5]. These events are coordinated by ovarian estrogen
and progesterone. Angiogenesis during decidualization is
required for a successful pregnancy, however the signaling
pathways that regulate this process have yet to be fully
characterized.
In mice and non-human primates, VEGF mediates
the increased uterine vascular permeability and deciduall Ltd. This is an Open Access article distributed under the terms of the Creative
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We have shown that the VEGF receptors (VEGFR-1,
VEGFR-2, and VEGFR-3) are expressed in distinct patterns
in the peri-implantation uterine decidua [9]. To investigate
the requirement for VEGF receptor signaling in the de-
cidua, we administered a single, peri-implantation (E3.75)
dose of blocking antibody against VEGFR-1, VEGFR-2,
or VEGFR-3, in a progesterone-replaced, ovariectomized
mouse model. Inhibition of VEGF-A receptor, VEGFR-2,
blocked decidual angiogenesis observed at E7.5 and re-
sulted in an aborted pregnancy prior to E10.5, while
VEGFR-3 inhibition moderately reduced decidual angio-
genesis but had no effect on pregnancy [9]. In contrast,
VEGFR-1 blockade at a single E3.75 time-point did not ef-
fect decidual angiogenesis or disrupt pregnancy [9].
Embryo implantation and trophoblast invasion create
a pro-inflammatory environment leading to the recruit-
ment of immune cells that mediate maternal tolerance
to the semi-allogeneic embryo [5,10]. Decidual macro-
phages are the second most abundant immune cell
population at the implantation site, comprising 20-30%
of immune cells in the uterine decidua [4,11,12]. Dys-
regulated macrophage activation in the decidua has
been implicated in recurrent miscarriages [13]. Decid-
ual macrophage numbers, as well as the proportion of
pro-apoptotic Fas ligand expressing decidual macro-
phages, are increased in spontaneous miscarriages [14].
Thus, understanding the signaling pathways that regulate
decidual macrophages may elucidate causes of early preg-
nancy failures.
Macrophages are closely associated with endothelial
cells during physiologic angiogenesis during ovarian cor-
pus luteum development and postnatal retinal develop-
ment, [15,16]. Activation of macrophage VEGFR-1 has a
role in macrophage recruitment to sites of active angio-
genesis [17,18]. Macrophages have been implicated in
promoting angiogenesis by releasing pro-angiogenic
factors such as VEGF-A and angiopoietin [15] and in
anastomosis, the formation of a bridge between two
angiogenic tip cells followed by vascular sprout fusion
[15,19]. Ablation of ovarian macrophages leads to signifi-
cant endothelial cell depletion and hemorrhage [16,20].
Macrophages have been implicated in the pregnant
uterus, including acting in the coordination of the maternal
immune response and promoting angiogenesis. However,
the relationship between decidual macrophages, endothe-
lial cells and VEGFR-1 has not been investigated.
VEGFR-1 binds VEGF-A, VEGF-B and placental growth
factor (PlGF) [21]. VEGFR-1 gene encodes two mRNA
splice variants. The full-length VEGFR-1 variant encodes a
membrane bound receptor with classic intracellular tyro-
sine kinase signaling that positively regulates angiogenesis.
The alternatively spliced variant encodes the VEGFR-1
extracellular domain resulting in a secreted protein knownas soluble VEGFR-1 (sFlt-1) that is anti-angiogenic [22,23].
sFlt-1 sequesters the VEGFR-2 ligand, VEGF-A as well as,
the VEGFR-1 specific ligands, VEGF-B and PlGF. Thus,
sFlt-1 functions as a negative regulator of both VEGFR-2
and full-length VEGFR-1 signaling and is necessary for
proper embryonic angiogenesis [23,24]. VEGFR-1 null
(Flt-1−/−) mutant embryos die because of an overgrowth of
vascular endothelial cells [24]. Mice with deletion of the
VEGFR-1 Tyrosine Kinase (TK) domain (Flt-1 TK−/−) are
viable and have normal blood vessel development, but
have altered macrophage migration [25]. In pathologic
conditions, such as cancer and inflammatory diseases,
full length VEGFR-1 signaling promotes angiogenesis and
activates/mediates migration of macrophage-lineage cells
[26]. Thus, the context and abundance of sFlt-1 and full-
length VEGFR-1 determine the pro- or anti-angiogenic
effect of VEGFR-1.
In this study, we determined the expression pattern of
VEGFR-1 with respect to endothelial cells and macro-
phages in the pre- and post-implantation uterus. VEGFR-1
neutralizing antibodies were administered prior to and dur-
ing implantation. Our goal was to determine if inhibition
of VEGFR-1 affects decidual angiogenesis, macrophage re-
cruitment, and/or the establishment and maintenance of
pregnancy in mice. Using two different VEGFR-1 blocking
antibodies, MF-1 and R&D Systems AF471 that prevent
ligand binding to VEGFR-1, we found that both vascular
density and macrophage recruitment to the pregnant
uterus were significantly reduced. Despite this, embryos
implanted in the uterus and pregnancy progressed after
VEGFR-1 blockade. We conclude that VEGFR-1 activity is
required for proper decidual angiogenesis and macrophage
recruitment to the implantation site during pregnancy.
Materials and methods
Animal model
The Columbia University Institutional Animal Care and
Use Committee approved animal studies. Adult wild-
type CD1 female mice and CD1 male mice of proven
fertility were used. When mice were bred, noon on the
day a mating plug was observed was designated embry-
onic day (E) 0.5. Uteri of non-pregnant female mice and
pregnant females at E3.5 and E6.5 were embedded in
Tissue-Tek® O.C.T.™ Compound (Sakura Fine Technical
Co, Ltd, Tokyo, Japan), snap-frozen on dry ice in ethanol
and stored at −80°C.
To determine the effect of continuous VEGFR-1
blockade, females were intraperitoneally (i.p.) injected
with VEGFR-1 blocking monoclonal antibody (MF-1,
132 mg/kg animal, ImClone Systems, Inc.; n = 5 mice),
anti-mouse VEGFR-1 antibody (AF471, 2 mg/kg animal,
R&D systems; n = 1 mice), or saline (n = 5 mice) every
3 days for 18 days. MF-1 has an elimination half-life of
3 days and reaches maximal plasma concentrations 6 hours
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final dose of antibody or saline was given on E3.5. Pregnant
females were sacrificed on E7.5. Implantation sites were
counted, uterine weight measured, and uteri freshly frozen
in O.C.T.™ compound for sectioning. Pregnant females
were sacrificed on E10.5 to determine the number of im-
plantation sites and uterine weight.
Histological staining
For uterine analyses, 5 μm transverse sections through
the non-pregnant and E3.5 uteri were generated. For
implantation site analyses, frontal sections through
uterus/implantation site were generated for E6.5 at
7 μm and for E7.5 with VEGFR-1 blockade at 12 μm.
Implantation was confirmed by H&E staining every
5th section. Specific staining was performed at least
3 times and 5 different uterine sections or implant-
ation sites were analyzed.
Sections were stained as previously described [27].
Primary antibodies included anti-mouse VEGFR-1 (R&D
Systems, AF471), anti-mouse F4/80 (eBioscience, 14–
4801), anti-mouse CD31 (BD Biosciences, 553370), anti-
mouse endomucin (Santa Cruz, sc-65495), anti-mouse
VE-cadherin (BD Biosciences, 550548), and anti-mouse
CD11b (Abcam ab8878). For IHC staining, biotin rabbit
anti-goat IgG (Vector, BA-5000), biotin goat anti-rat IgG
(BD Biosciences, 559286), the avidin/biotin blocking kit
(Vector, SP-2001), the Vectastain ABC kit and DAB sub-
strate kit (Vector, SK-4100) were used. Sections were
counterstained with hematoxylin. For IF experiments, the
following secondary antibodies were used: donkey anti
goat-IgG Alexa-Fluor 594 (Invitrogen, A11058) and don-
key anti rat-IgG Alexa-Fluor 488 (Invitrogen, A2108).
Slides were covered with Vectashield containing with 4′,
6-diamidino-2-phenylindole (Vector, H-1200) for nuclear
visualization.
Imaging
IHC and H&E staining images were captured with a
Nikon Eclipse E800 microscope and Nikon DXM 1200
digital camera and NIS-Elements D3.10 software or
ImagePro Plus v.4.01 software. Fluorescent images were
captured using a Nikon A1 scanning confocal microscope
on an Eclipse Ti microscope stand (Nikon Instruments,
Melville, NY). Standard lasers and filters were used
to image DAPI, AlexaFluor 488, and TRITC. Images
were taken using the 10×/0.4 and 60×/1.49 objectives.
Representative Z-stacked maximum intensity images are
shown.
Quantitation of decidual macrophage and vascular density
The percentage of decidua occupied by blood vessels or
macrophages was calculated from E7.5 decidua frontal
uterine sections by dividing the total area of CD31 orF4/80 staining by the area of the decidua multiplied by
100. Images were captured using a Nikon Eclipse E800
microscope and Nikon DXM 1200 digital camera, and
data were processed using ImagePro Plus Version 4.01
(Media Cybernetics) [28].
Serum progesterone levels
Blood was obtained from all animals by cardiopuncture.
Serum progesterone levels were measured using a
competitive chemiluminescent immunoassay (Diagnostic
Products Corp./Siemens) [9].
Statistical analysis
Data are presented as mean ± standard error of the mean
(sem). Unpaired Student t-test was used to compare
sample means. P < 0.05 was considered a statistically sig-
nificant difference. Statistical analyses were performed
using the Statistical Package for Social Science version
15.0 (SPSS, Inc., Chicago, Il).
Results
Endothelial and macrophage expression of VEGFR-1
in the peri-implantation uterus
We determined the expression of VEGFR-1 in uterine
endothelial cells (ECs) and macrophages in the post-
implantation murine decidua at E6.5 (Figure 1). To de-
termine EC expression, VEGFR-1 was co-stained with
three endothelial cell markers, CD31 [9,28,29], endomucin
[30] and VE-cadherin [31,32]. To determine macrophage
VEGFR-1 expression, uterine sections were stained for
VEGFR-1 and either the monocyte marker, CD11b [33,34]
or the macrophage marker, F4/80 [35-37].
At E6.5, the embryo is readily detected in the post-
implantation uterus (Figure 1A). VEGFR-1+ cells are
most abundant in the decidua directly surrounding
the implanted embryo or the primary decidual zone
(Figure 1B–F). CD31+ and endomucin+ ECs are observed
throughout the decidua (Figure 1B, C), while VE-cadherin+
ECs are most abundant in the anti-mesometrial decidua
(Figure 1D). The positive VE-cadherin staining dir-
ectly adjacent to the implanted embryo does not have
a vascular pattern and does not represent ECs (Figure 1D).
VEGFR-1 is expressed in decidual ECs that express
CD31 (Figure 1B), endomucin (Figure 1C) or VE-cadherin
(Figure 1D). CD11b+ monocytes and F4/80+ macrophages
are scattered throughout the decidua, but their distribu-
tion patterns differ (Figure 1E, F). VEGFR-1 expression is
not detected in CD11b+ or F4/80+ decidual monocytes/
macrophages (Figure 1E, F), in contrast to VEGFR-1 ex-
pression in decidual ECs. VEGFR-1 is expressed in cells
that are directly adjacent to decidual monocytes/macro-
phages. Since VEGFR-1 expression closely overlaps with
CD31 expression, CD31 was used as the EC marker for all
additional experiments.
Figure 1 VEGFR-1 expression in endothelial cells and macrophages in the post-implantation uterus. H&E and double staining IF were performed
on E6.5 frontal uterine sections. (A) H&E of a post-implantation mouse uterus showing the embryo (e), anti-mesometrial (am) and mesometrial (m) areas.
(B-F) VEGFR-1+ cells (red) are observed in the decidua, with abundant expression in the primary decidual zone surrounding the implanted embryo.
(B) Double-staining for VEGFR-1+ (red) and CD31+ (green) cells demonstrates expression of VEGFR-1 in a subset of CD31+ ECs. (C) Double-staining for
VEGFR-1+ (red) and endomucin+ (green) cells demonstrates expression of VEGFR-1 in a subset of endomucin+ ECs. (D) Double-staining for VEGFR-1+ (red)
and VE-cadherin+ (green) cells demonstrates expression of VEGFR-1 in VE-cadherin+ ECs. (E) Double-staining for VEGFR-1+ (red) and CD11b+ (green) cells
demonstrates that VEGFR-1 is not expressed in CD11b+ monocytes. (F) Double-staining for VEGFR-1+ (red) and F4/80+ (green) cells demonstrates that
VEGFR-1 is not expressed in F4/80+ macrophages. VEGFR-1+ cells are adjacent to CD11b+ monocytes and F4/80+ macrophages. White boxes in
(B-F) indicate areas of the uteri magnified below (B1-F1). (A-F) Scale bar = 500 μm. (B1-F1) Scale bar = 20 μm.
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non-pregnant uterus
In the non-pregnant uterus, CD31+ ECs and F4/80+ mac-
rophages are distributed throughout the surroundingstroma and myometrium, but excluded from the uterine
lumen and tubular endometrial glands that are lined
by a single layer of columnar epithelium (Figure 2A–C).
VEGFR-1 expression is restricted to a subset of stromal
Figure 2 VEGFR-1, CD31 and F4/80 expression in the non-pregnant uterus. IHC and double staining IF were performed on non-pregnant
uterine cross-sections. (A) Schematic representation of a non-pregnant mouse uterus showing lumen (arrowheads), endometrial glands, stroma (s),
and myometrium (myo). (B) ECs, detected by CD31 staining (brown), are observed throughout the stroma and myometrium. (C) Macrophages,
detected by F4/80 staining (brown), are observed throughout the stroma and myometrium. (D) Double-staining for VEGFR-1+ (red) and
CD31+ (green) demonstrates expression of VEGFR-1 in a subset of CD31+ ECs throughout the stroma. (E, F) VEGFR-1+ cells (red) and F4/80+
macrophages (green) are distributed throughout the stroma. VEGFR-1 and F4/80 co-expression is not observed. The inset (F) highlights
contact of adjacent VEGFR-1+ cells and F4/80+ macrophages. (G, H) IF controls with secondary antibodies alone show no specific staining. L, lumen;
g, endometrial gland. (B, C) Scale bar = 100 μm. (D-H) Scale bar = 50 μm.
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macrophages, but is expressed on cells adjacent to stromal
macrophages (Figure 2E, F).
VEGFR-1 is expressed in endothelial cells of the
pre-implantation uterus
By E3.5, progesterone secretion by ovarian corpora lutea
has been initiated to prepare the endometrium for em-
bryo implantation. The gross appearance of the E3.5
pre-implantation uterus is similar to the non-pregnant
uterus (Figures 2A and 3A). As in the non-pregnantstate, CD31+ ECs (Figure 3B) and F4/80+ macrophages
(Figure 3C) are distributed throughout the stroma and
myometrium. Similar to the non-pregnant state, CD31+
ECs and F4/80+ macrophages (Figure 3C, F) are abundant
adjacent to the lumen and glands at E3.5. VEGFR-1+
cells are observed throughout the stroma (Figure 3D).
VEGFR-1 expression was cell associated consistent with
the antibody detecting full-length VEGFR-1 on the cell
surface (Figure 3E, inset). Co-staining with CD31 reveals
that most VEGFR-1+ cells are ECs (Figure 3E). As in the
non-pregnant state, VEGFR-1+ cells are found adjacent
Figure 3 VEGFR-1, CD31, F4/80, and CD11b expression in the pre-implantation mouse uterus. IHC and double staining IF were performed
on E3.5 uterine cross-sections. (A) Schematic representation of an E3.5 mouse uterus showing lumen (arrowheads), glands, stroma (s), and
myometrium (myo). (B) ECs, detected by CD31 staining (brown), are observed throughout the stroma and myometrium, similar to the
non-pregnant state. (C) Macrophages, detected by F4/80 staining (brown), are observed throughout the stroma and are abundant adjacent to the
lumen and glands at E3.5. (D) VEGFR-1+ cells (brown), are distributed throughout the stroma and cell associated VEGFR-1 expression highlighted in
the inset. (E) Double staining for VEGFR-1 (red) and CD31 (green) demonstrates expression of VEGFR-1 on CD31+ ECs throughout the stroma.
(F) VEGFR-1+ cells (red) and F4/80+ macrophages (green) are distributed throughout the stroma. VEGFR-1 and F4/80 co-expression is not observed.
(G) VEGFR-1+ cells (red) and CD11b+ monocytes (green) are distributed throughout the stroma. VEGFR-1 and CD11b co-expression is not observed.
L, lumen. Scale bars B, C = 100 μm. Scale bars D – F = 50 μm.
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cytes (Figure 3G).
VEGFR-1 is expressed in endothelial cells of the
post-implantation uterus
With embryo-uterine contact during implantation, stro-
mal cells are transformed into large, polygonal, glycogen
and lipid rich decidual cells. By E6.5, the primary and
secondary decidual zones are defined by morphologic
differences in decidual cells, as well as differential ex-
pression of tight junction proteins and VEGF recep-
tors [9,29,38,39] (Figure 4A). CD31+ ECs are abundant
throughout the decidua, the endometrium surrounding the
implanted embryo, and myometrium (Figure 4B, F, and G).
F4/80+ macrophages are scattered throughout the deciduaand most abundant in the myometrium and stroma dir-
ectly adjacent to the myometrium (Figure 4C, I, J).
Within the decidua, the secondary decidual zone (SDZ)
contains the highest concentration of F4/80+ macro-
phages (Figure 4C). VEGFR-1+ cells are most abundant
in the primary decidual zone (PDZ) (Figure 4D, E, H).
Most VEGFR-1+ cells are ECs (Figure 4E) and within
the PDZ, VEGFR-1+ cells are found adjacent to F4/80+
macrophages (Figure 4H). As in the pre-implantation
uterus, VEGFR-1 expression in decidual ECs is consistent
with full-length VEGFR-1 (Figure 4E, H, insets). The dis-
tribution pattern of VEGFR-1+ ECs and macrophages sug-
gests that VEGFR-1+ EC and F4/80+ macrophages are in
direct contact in both the non-pregnant, peri-implantation
and post-implantation uterus.
Table 1 Effect of anti-VEGFR-1 blocking antibody MF-1 on pregnancy, decidual macrophages and vascular density
Anti-VEGFR-1 (MF-1) Control
E7.5 E10.5 E7.5 E10.5
Implantation sites (#) 13 ± 0.6 12.1 ± 0.4 13 ± 0.3 11.8 ± 0.9
Uterine weights (g) 0.35 ± 0.01 2.1 ± 0.1 0.36 ± 0.02 2.3 ± 0.1
Serum progesterone (ng/mL) 23.4 ± 2.3 27.9 ± 1.1
Macrophage density 6.7 × 10−5 ± 1.1 × 10-6a 2.5 × 10−5 ± 4.3 × 10-7a
Vascular density 13.1 ± 0.2b 6.3 ± 0.2b
a, bP < 0.01.
Figure 4 VEGFR-1, CD31, and F4/80 in the post-implantation mouse uterus. IHC and double staining IF were performed on E6.5 frontal
uterine sections. (A) Schematic representation of an E6.5 mouse uterus showing the embryo (e), anti-mesometrial (am) and mesometrial (m) areas,
and myometrium (myo). (B) CD31+ ECs (brown) are abundant in the decidua around the implanted embryo and the myometrium. (C) A majority
of F4/80+ macrophages (green) are observed in the secondary decidual zone (SDZ) and myometrium. (D) A majority of VEGFR-1+ cells (brown)
are observed in the primary decidual zone (PDZ) directly adjacent to the implanted embryo. (E-F) Double staining of VEGFR-1 (red) and CD31+ (green)
demonstrates (E) co-expression in the ECs within the PDZ (inset), (F, G) and minimal co-expression of VEGFR-1 and CD31 in the abundant ECs in the
SDZ of the anti-mesometrial and mesometrial poles. (H) Double staining for VEGFR-1 (red) and F4/80+ (green) shows VEGFR-1+ cells adjacent to
F4/80+ macrophages in the PDZ (inset). (I, J) F4/80+ macrophages are abundant in the SDZ of the anti-mesometrial pole and mesometrial poles,
where VEGFR-1 expression is low to absent. (B-D, H) Scale bars = 100 μm. (F, G, I, J) Scale bars = 50 μm.
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Figure 5 VEGFR-1 blockade reduces peri-implantation macrophage and vascular density at E7.5. (A, B) Double staining for F4/80 (green)
and CD31 (red) in E7.5 uterine frontal sections from mice treated with VEGFR-1 blocking antibodies (MF-1 or AF471) or from control mice.
Reduced expression of F4/80 and CD31 is observed in treatment groups. Scale bars = 50 μm. (C, D) F4/80+ or CD31+ signal was determined
and normalized by total decidual area. F4/80+ macrophage and CD31+ EC density is significantly reduced in uteri of mice that received MF-1
compared to controls.
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macrophages and vascular density
Previous studies demonstrated that a single dose of
VEGFR-1 blocking antibody MF-1, administered on
E3.75, had no effect on decidual angiogenesis or preg-
nancy [9]. In this study, we administered 6 doses of MF-1
prior to mating and a single dose on E3.5, one day prior
to implantation, to determine the effect of continuous
VEGFR-1 blockade on pregnancy. Administration of
VEGFR-1 blocking antibody MF-1 had no effect on the
number of implantation sites or uterine weights at E7.5
and E10.5 (Table 1). Histological analysis of uterine tis-
sues sections confirmed normal embryonic development
at E7.5 and E10.5 (data not shown). However, differences
in macrophage and vascular density were observed. At
E7.5, F4/80+ macrophage and CD31+ EC densities were
both significantly decreased in MF-1 treated uteri com-
pared to controls (Figure 5 and Table 1). VEGFR-1 block-
ade with R&D Systems AF471 antibody also resulted in
decreased macrophage numbers and vascular density at
E7.5 (Figure 5B).
To confirm that blocking VEGFR-1 did not affect ovarian
function, we measured serum progesterone levels at E7.5.
The mean serum progesterone level was similar in MF-1
treated mice and controls (23.4 ± 2.3 vs. 27.9 ± 1.1 ng/mL,
Table 1), indicating that VEGFR-1 blockage did not affect
corpora lutea function in this model. Thus, the observed
uterine defects can be attributed to the direct affects of
VEGFR-1 blockade on the uterus.
Discussion
We have previously shown that peri-implantation inhib-
ition of VEGFR-2 significantly reduces vascular density
and causes pregnancy loss by E10.5. We showed that
only a subset of endothelial cells express VEGFR-1 and
peri-implantation inhibition with a single dose of VEGFR-1
blocking antibody at E3.75 does not affect vascular density
or pregnancy [9]. Our present evaluation of VEGFR-1 ex-
pression with respect to endothelial cells and macrophages
shows that VEGFR-1 expression is mainly restricted to
uterine and decidual endothelial cells, while VEGFR-1
is not expressed in monocytes and macrophages. Endo-
thelial cells expressing VEGFR-1 were often in direct con-
tact with CD11b+ monocytes and F4/80+ macrophages.
Finally repeated pre-implantation injections of a VEGFR-1
blocking antibody, significantly decrease both the numberof macrophages and vascular density in the decidua of E7.5
pregnant mice. Taken together, our results suggest that the
decreased vascularity observed at E7.5 is a direct result of
VEGFR-1 blockade, whereas the reduction in macrophages
may be an indirect result of the decrease in VEGFR-1 func-
tion in the endothelial cells.
Treatment with MF-1, which blocks binding of VEGF-A
and PlGF to VEGFR-1, can have pro- or anti-angiogenic ef-
fects, depending on the context of VEGFR-1 function
[26,40-42]. PlGF signaling, via membrane-localization of
full length VEGFR-1, plays a pro-angiogenic role in patho-
logical angiogenesis [26,42]. In murine decidual angio-
genesis, VEGFR-1 appears to be membrane associated
consistent with full-length receptor expression (Figures 1
and 3E, H). Thus, the reduced angiogenesis we observed
is likely due to blocking ligand-dependent VEGFR-1 pro-
angiogenic signaling. However, it has been previously
shown that the VEGFR-1 TK domain is not necessary
for murine decidual angiogenesis [29]. Thus the pro-
angiogenic role for VEGFR-1, we observed may be inde-
pendent of VEGFR-1 TK signaling pathway.
We have shown that a single dose of MF-1 adminis-
tered within 24 hours of implantation does not affect
vascular density [9], but continuous VEGFR-1 blockade
results in a 48% reduction in vascular density (Figure 5D).
A greater than 50% reduction in decidual vascular density
with VEGFR-2 blockade results in pregnancy loss, likely
due to loss of angiogenesis in both the primary and
secondary decidual zones [9]. In contrast, inhibition of
VEGFR-3 results in a less than 50% decrease in primary
decidual zone angiogenesis, but does not lead to pregnancy
loss [9]. Combined, these data suggest that implantation
and early pregnancy can tolerate a less than 50% reduction
of vascular density in the primary decidual zone.
Macrophages are prominent in the adult ovary and
uterus, two organs with physiological cyclical angiogen-
esis regulated by the VEGF/VEGFR-2 signaling pathway
[9,28,43]. The number and phenotype of macrophages in
the non-pregnant uterus changes with the ovarian cycle
and additional macrophages are recruited into the endo-
metrium during the peri-implantation period [20,44]. It
has been shown that pre-implantation macrophage abla-
tion prevents embryo implantation and results in infertility
[20]. However, fertility is restored when macrophage-
depleted mice are supplemented with exogenous proges-
terone suggesting a defect in corpora lutea function. In
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lutea development and function, specifically the synthesis
of progesterone that is required for embryo implantation
and establishing pregnancy [20,45]. Thus, uterine macro-
phages may not be necessary for embryo implantation. We
found that pregnancy can tolerate a reduction of macro-
phages by 37% of normal. Taken together, the data suggest
that macrophages do not have an obligatory role in the
uterine decidualization and implantation of the embryo.
However the role of macrophages after embryo implant-
ation still remains to be elucidated.
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